Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment

BACKGROUND: Immune checkpoint inhibitors (ICIs) represent a promising novel class of cancer therapy, but immune-mediated adverse events can complicate ICI treatment. Acute cholecystitis in patients receiving ICI therapy has not been characterized. We aimed to describe the clinical features of patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Abu-Sbeih, Hamzah, Tran, Cynthia Nguyen, Ge, Phillip S., Bhutani, Manoop S., Alasadi, Mazen, Naing, Aung, Jazaeri, Amir A., Wang, Yinghong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499962/
https://www.ncbi.nlm.nih.gov/pubmed/31053161
http://dx.doi.org/10.1186/s40425-019-0604-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499962/
https://www.ncbi.nlm.nih.gov/pubmed/31053161
http://dx.doi.org/10.1186/s40425-019-0604-2

Ejemplares similares